Triomune (Stavudine + Lamivudine + Nevirapine)

Triomune (Stavudine + Lamivudine + Nevirapine)

Brand Name: Triomune
Strength: 30mg / 40mg
Contents: Triomune 30: Stavudine 30mg + Lamivudine 150mg + Nevirapine 200mg
Triomune 40: Stavudine 40mg + Lamivudine 150mg + Nevirapine 200mg
Form: Tablet
Manufacturer Cipla
Pricing: Price per Pack of 30 Caps

Triomune is a combination of 3 drugs commonly used in the management of Human Immunodeficiency Virus (HIV) infection. Both stavudine and lamivudine belong to the nucleoside analogue class of antiretroviral drugs. Both drugs act by terminating the growth of the DNA chain and inhibiting the reverse transcriptase of HIV. Nevirapine is a non-nucleoside reverse transcriptase inhibitor. It acts by directly inhibiting reverse transcriptase. Studies using the combination of stavudine + lamivudine + nevirapine have demonstrated its efficacy in patients with HIV infection. In the study presented by Kaspar et al at the 5th Conference on Retroviruses and Opportunistic Infections, Chicago 1998, 87% of patients had undetectable viral loads at 33-44 weeks. In the study presented by Russell et al at the 7th European Conference on Clinical Aspects and Treatment of HIV Infection, Lisbon 1999, CD4 counts increased by 195 cells/mm3 and 230 cells/mm3 in patients with low (80,000 copies/ml) groups, respectively at the end of 1 year. 72% of patients with low viral loads and 80% of patients with high viral loads had undetectable viral loads at the end of 1 year. Each tablet of Triomune contains half of the commonly prescribed daily doses of stavudine, lamivudine and nevirapine. All three drugs are to be administered twice daily, permitting a fixed-dose combination to be formulated. With the availability of this combination formulation, patients may be better able to adhere to triple drug regimens, thereby enhancing compliance.

Indications
Triomune is indicated for the treatment of HIV infection, once patients have been stabilized on the maintenance regimen of nevirapine 200 mg bd, and have demonstrated adequate tolerability to nevirapine.